Argen-X (ARGX)
Euronext Brussels · Belgium · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 783.40 |
|---|---|
| 52-week range | 568.40 – 925.00 |
| Return, 1 month / 3 months | −8.4% / +3.3% |
| Return, 1 year / 3 years | +10.5% / +72.8% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 48 |
| Volatility (1 year) | 39.8% |
| Worst drawdown (1 year) | -27.4% |
| Average daily value traded | 70.20M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Argenx is a biopharmaceutical company that develops antibody-based medicines for serious autoimmune diseases. Its main commercial product is an antibody fragment designed to reduce disease-causing antibodies, used in the treatment of generalized myasthenia gravis and other autoimmune conditions. The company carries out research and clinical development and sells its medicines through its own commercial organization. Argenx is headquartered in the Netherlands, with a significant presence in Belgium and the United States, and serves patients and physicians in multiple markets around the world.
On this site Argen-X appears as a stock on the Euronext Brussels (Belgium), code ARGX, with prices in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Argen-X (ARGX) trades on the Euronext Brussels in Belgium. It last closed at EUR 783.40 on 22 October 2026.
Its price-based Market X-Ray is 71 out of 100 (a strong price profile), ranking 17 of 111 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 10.5% and over the last three months it rose 3.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Brussels
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 78 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 5.8% | ||
| From 52-week high | -14.1% | ||
| Momentum | 81 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 3.3% | ||
| 6-month return | 15.5% | ||
| 12-month return, skipping the last month | 20.6% | ||
| Stability (higher is calmer) | 35 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 39.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -27.4% | ||
| Liquidity | 100 · Strong | Trades actively. | |
| Average daily value traded | 70.20M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +3.3% |
|---|---|
| 1 month | −8.4% |
| 3 months | +3.3% |
| 6 months | +15.5% |
| 1 year | +10.5% |
| 3 years | +72.8% |
| 5 years | +213.9% |
Signals
| 50-day / 200-day average | 835.54 / 740.43 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 32.27 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Brussels; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.